Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers
Seeking Alpha News (Thu, 15-Jan 7:10 AM ET)
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Globe Newswire (Mon, 12-Jan 8:47 AM ET)
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
PRNewswire (Wed, 17-Dec 4:12 PM ET)
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Globe Newswire (Mon, 8-Dec 4:10 PM ET)
Globe Newswire (Thu, 6-Nov 7:00 AM ET)
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
Globe Newswire (Mon, 3-Nov 8:30 AM ET)
Globe Newswire (Wed, 29-Oct 8:30 AM ET)
ACHV Names Erik Atkisson Chief Legal Officer Amid Critical FDA Review for Cytisinicline
Market Chameleon (Tue, 21-Oct 6:31 AM ET)
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Globe Newswire (Mon, 20-Oct 8:30 AM ET)
Market Chameleon (Fri, 17-Oct 6:31 AM ET)
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Achieve Life Sciences - Common Shares trades on the NASDAQ stock market under the symbol ACHV.
As of January 20, 2026, ACHV stock price declined to $5.49 with 929,139 million shares trading.
ACHV has a beta of 2.22, meaning it tends to be more sensitive to market movements. ACHV has a correlation of 0.18 to the broad based SPY ETF.
ACHV has a market cap of $292.25 million. This is considered a Small Cap stock.
In the last 3 years, ACHV traded as high as $10.30 and as low as $1.84.
The top ETF exchange traded funds that ACHV belongs to (by Net Assets): VTI, VXF, IWC.
ACHV has outperformed the market in the last year with a price return of +78.8% while the SPY ETF gained +15.8%. ACHV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +78.2% and +10.5%, respectively, while the SPY returned +2.9% and -0.8%, respectively.
ACHV support price is $5.61 and resistance is $6.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHV shares will trade within this expected range on the day.